ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Open accessThe DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
Abstract
Advanced Breast Cancer (ABC) is a treatable but still generally incurable disease. The goals of care are to optimize both length and quality of life. Due to continuous research, several advances have been made, particularly for the HER-2-positive and for Luminal-like subtypes. Notwithstanding these advances, median overall survival of patients with ABC is still only 2e3 years, although the range is wide, and survival may be longer for patients treated in specialized institutions. Implementation of current knowledge is highly variable among countries and within each country. The use of treatment guidelines has been associated with a significant improvement in survival. This has been achieved mainly in early breast cancer. For ABC, and particularly metastatic breast cancer (MBC), less level 1 evidence exists and only recently have international consensus guidelines been developed (ABC1 e). The ABC Consensus Conference was created by the European School of Oncology (ESO) with the ambitious goal of improving outcomes for all patients with advanced breast cancer. Backed by strong political advocacy, ABC guidelines are seeking to improve standards of care, to raise awareness about how to best meet to the needs of this underserved group of patients, and to identify research priorities so that clinical research is focused on the most important areas of unmet need. Following the work of the ESO-ABC Task Force, created in 2005, and the successful undertaking of the 1st International Consensus Guidelines Conference on ABC (ABC1), held in November 2011, the 2nd International Consensus Conference for Advanced Breast Cancer (ABC2) took place in Lisbon, Portugal, on
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“For HER-2-positive LABC, anthracyclines should not be administered concurrently with trastuzumab since this approach does not increase the pCR rate, and it could increase the risk of cardiac toxicity, based largely on studies in the metastatic setting [35,36].”
BackgroundSelf-citationTrastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834 · cited 2×
“lapatinib plus capecitabine in the subset of 118 patients who were randomized in the first-line setting, having relapsed on or within 6 months of adjuvant trastuzumab, appeared similar to the effect seen in the overall trial [100].”
BackgroundResultSelf-citationEverolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863 · cited 1×
“The mTOR inhibitor everolimus when added to exemestane, in patients progressing on non-steroidal aromatase inhibitor, provided a significant PFS prolongation of about 5 months [89,90].”
BackgroundSelf-citationPertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532 · cited 1×
“The CLEOPATRA trial [96,97]; showed superior results, in terms of PFS (18.”
ResultEarly palliative care for patients with advanced cancer: a cluster-randomised controlled trial
Zimmermann, C., Swami, N., Krzyzanowska, M., Hannon, B., Leighl, N., Oza, A., Moore, M., Rydall, A., Rodin, G., Tannock, I., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62416-2 · Cited by 1,781 · cited 1×
“The multidisciplinary approach of ABC should encompass early in the history of the disease not only physical, but also functional, social, psychological, and spiritual, domains [25–27].”
BackgroundMiller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306 · cited 1×
“Capecitabine has shown consistent results as first- and second-line therapy [104–112].”
ResultSelf-citationGrading Strength of Recommendations and Quality of Evidence in Clinical Guidelines
Guyatt, G., Gutterman, D., Baumann, M. H., Addrizzo-Harris, D., Hylek, E. M., Phillips, B., Raskob, G., Lewis, S. Z., & Schünemann, H. (2006) · Chest · doi:10.1378/chest.129.1.174 · Cited by 1,220 · cited 1×
“Table 1 describes the grading system used [15].”
MethodCortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094 · cited 1×
“Eribulin has provided an OS benefit in heavily pretreated patients (up to 5 lines of treatment) [115] and similar PFS and OS results to capecitabine after prior treatment with an anthracycline and taxane [116].”
ResultSelf-citationRobert, N. J., Diéras, V., Glaspy, J., Brufsky, A. M., Bondarenko, I., Lipatov, O. N., Perez, E. A., Yardley, D. A., Chan, S. Y. T., Zhou, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0982 · Cited by 1,064 · cited 1×
“Capecitabine has shown consistent results as first- and second-line therapy [104–112].”
Resultvon Minckwitz, G., Schneeweiss, A., Loibl, S., Salat, C., Denkert, C., Rezai, M., Blohmer, J. U., Jackisch, C., Paepke, S., Gerber, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70160-3 · Cited by 1,022
Research works printed but not linked: 2
- Piccart-Gebhart, 2014, J Clin Oncol, 32
- Wildiers, 2013, T-DM1 for HER2-positive metastatic breast cancer (MBC): primary results from TH3RESA, a phase 3 study of T-DM1 vs treatment of physician's choice, Presented at the European Cancer Congress
Cited by
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.66 · Cited by 3,079
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
“Visceral crisis and endocrine resistance have been defined during ABC 2 and published [1].”
InfluentialSelf-citationSledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680
“MONARCH 2 evaluated patients whose disease progressed while they were receiving neoadjuvant or adjuvant ET, # 12 months after adjuvant ET, or while receiving ET for ABC.”
BackgroundInfluentialSelf-citationGennari, A., André, F., Barrios, C. H., Cortés, J., de Azambuja, E., DeMichele, A., Dent, R., Fenlon, D., Gligorov, J., Hurvitz, S. A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.019 · Cited by 1,417
“MBC after therapy for EBC tends to have a more aggressive tumour biology and a worse outcome compared with de novo MBC. 14,15 In a retrospective cohort study covering the period 1990-2010, 14 de novo MBC incidence rates remained constant whereas subsequent MBC decreased.”
BackgroundInfluentialSelf-citation5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369
“For the purpose of advanced breast cancer (ABC) guidelines, ABC comprises both inoperable locally advanced breast cancer (LABC) and metastatic breast cancer (MBC).(1,2) Advanced/metastatic breast cancer remains a virtually”
Self-citation4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,171
“As already extensively discussed in previous editions, the main recommendation for these patients is the induction of OFS/OFA, to which an additional endocrine agent should be added [1, 11].”
BackgroundInfluentialSelf-citationDiéras, V., Miles, D., Verma, S., Pegram, M., Welslau, M., Baselga, J., Krop, I. E., Blackwell, K., Hoersch, S., Xu, J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30312-1 · Cited by 667
Self-citationRobertson, J. F. R., Bondarenko, I. M., Trishkina, E., Dvorkin, M., Panasci, L., Manikhas, A., Shparyk, Y., Cardona-Huerta, S., Cheung, K.-L., Philco-Salas, M. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32389-3 · Cited by 582
Baselga, J., Im, S.-A., Iwata, H., Cortés, J., De Laurentiis, M., Jiang, Z., Arteaga, C. L., Jonat, W., Clemons, M., Ito, Y., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30376-5 · Cited by 533
Duffy, M. J., Harbeck, N., Nap, M., Molina, R., Nicolini, A., Senkus, E., & Cardoso, F. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.017 · Cited by 522
“Recently, several expert panels, including ASCO [45], NCCN [22] and ABC [39], rec- ommended that the first-line therapy for patients with HER2-positive advanced breast cancer should be tras- tuzumab, pertuzumab and a taxane, if not previously treated with trastuzumab.”
BackgroundInfluentialSelf-citationPhase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma
Keyaerts, M., Xavier, C., Heemskerk, J., Devoogdt, N., Everaert, H., Ackaert, C., Vanhoeij, M., Duhoux, F. P., Gevaert, T., Simon, P., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.162024 · Cited by 429
“Because of this discordance, the European guidelines now recommend that a biopsy of a metastatic lesion be obtained to reassess biologic markers (11).”
BackgroundPerez, E. A., Barrios, C., Eiermann, W., Toi, M., Im, Y.-H., Conte, P., Martin, M., Pienkowski, T., Pivot, X., Burris, H. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.4887 · Cited by 420
“Patients Eligible patients had HER2-positive (immunohistochemistry 3+ and/ or in situ hybridization positive, prospectively and centrally confirmed at Targos Molecular Pathology GmbH [Kassel, Germany]) advanced breast cancer—that is, unresectable, progressive or recurrent locally advanced, or previously untreated MBC.…”
BackgroundInfluentialSelf-citationBardia, A., Mayer, I. A., Diamond, J. R., Moroose, R. L., Isakoff, S. J., Starodub, A. N., Shah, N. C., O’Shaughnessy, J., Kalinsky, K., Guarino, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.8297 · Cited by 412
Cardoso, F., Bartlett, J. M. S., Slaets, L., van Deurzen, C. H. M., van Leeuwen-Stok, E., Porter, P., Linderholm, B., Hedenfalk, I., Schröder, C., Martens, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx651 · Cited by 405
“The Advanced Breast Cancer (ABC) International Consensus Guidelines state that in metastatic male BC patients who need treatment with an aromatase inhibitor, a concomitant LHRH agonist or orchiectomy is preferred [12, 13].”
BackgroundSelf-citationGebhart, G., Lamberts, L. E., Wimana, Z., Garcia, C., Emonts, P., Ameye, L., Stroobants, S., Huizing, M., Aftimos, P., Tol, J., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv577 · Cited by 355
“Upon disease relapse, current guidelines recommend a biopsy to check the current molecular profile of the tumor [6, 7].”
BackgroundSinn, B. V., Fu, C., Lau, R., Litton, J., Tsai, T.-H., Murthy, R., Tam, A., Andreopoulou, E., Gong, Y., Murthy, R., et al. (2019) · npj Breast Cancer · doi:10.1038/s41523-019-0111-0 · Cited by 354
Global analysis of advanced/metastatic breast cancer: decade report (2005-2015)
Cardoso, F., Spence, D., Mertz, S., Corneliussen-James, D., Sabelko, K., Gralow, J., Cardoso, M.-J., Peccatori, F., Paonessa, D., Benares, A., et al. (2018) · The Breast · doi:10.1016/j.breast.2018.03.002 · Cited by 324
Self-citationBrain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study
Martin, A. M., Cagney, D. N., Catalano, P. J., Warren, L. E., Bellon, J. R., Punglia, R. S., Claus, E. B., Lee, E. Q., Wen, P. Y., Haas-Kogan, D. A., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0001 · Cited by 301
Verma, S., Bartlett, C. H., Schnell, P., DeMichele, A. M., Loi, S., Ro, J., Colleoni, M., Iwata, H., Harbeck, N., Cristofanilli, M., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0097 · Cited by 249
Self-citationIntrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer
Cejalvo, J. M., Martínez de Dueñas, E., Galván, P., García-Recio, S., Burgués Gasión, O., Paré, L., Antolín, S., Martinello, R., Blancas, I., Adamo, B., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2717 · Cited by 245
“Despite new systemic treatment advances, metastatic breast cancer is still an incurable disease and a major cause of cancer-related death (1).”
Ong, W. L., Schouwenburg, M. G., van Bommel, A. C. M., Stowell, C., Allison, K. H., Benn, K. E., Browne, J. P., Cooter, R. D., Delaney, G. P., Duhoux, F. P., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.4851 · Cited by 241
Self-citationCardoso, F., Paluch-Shimon, S., Schumacher-Wulf, E., Matos, L., Gelmon, K., Aapro, M. S., Bajpai, J., Barrios, C. H., Bergh, J., Bergsten-Nordström, E., et al. (2024) · The Breast · doi:10.1016/j.breast.2024.103756 · Cited by 237
Self-citationEllis, M. J., Llombart-Cussac, A., Feltl, D., Dewar, J. A., Jasiówka, M., Hewson, N., Rukazenkov, Y., & Robertson, J. F. R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.5831 · Cited by 238
PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials
Dey, N., De, P., & Leyland-Jones, B. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.037 · Cited by 229
“Due to its high efficacy and favorable tolerability, endocrine therapy is the treatment of choice for patientswith an advanced hormone receptor-positive tumor with the only exception of acute life-threatening disease (Cardoso et al., 2014; Partridge et al., 2014).”
BackgroundSecond international consensus guidelines for breast cancer in young women (BCY2)
Paluch-Shimon, S., Pagani, O., Partridge, A. H., Bar-Meir, E., Fallowfield, L., Fenlon, D., Friedman, E., Gelmon, K., Gentilini, O., Geraghty, J., et al. (2016) · The Breast · doi:10.1016/j.breast.2015.12.010 · Cited by 227
Self-citationTrastuzumab in the Treatment of Breast Cancer
Maximiano, S., Magalhães, P., Guerreiro, M. P., & Morgado, M. (2016) · BioDrugs · doi:10.1007/s40259-016-0162-9 · Cited by 223
Systemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanoma
Chamberlain, M. C., Baik, C. S., Gadi, V. K., Bhatia, S., & Chow, L. Q. M. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now197 · Cited by 223
Galdy, S., Lamarca, A., McNamara, M. G., Hubner, R. A., Cella, C. A., Fazio, N., & Valle, J. W. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9645-x · Cited by 209
“AntiHER2 therapy options might include the antibodies trastuzumab, pertuzumab, or trastuzumab emtansine (T-DM1) or the small-molecule, orally active, TKI, lapatinib [6, 90, 91].”
Advances in the treatment of advanced oestrogen-receptor-positive breast cancer
Turner, N. C., Neven, P., Loibl, S., & Andre, F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32419-9 · Cited by 205
Saghatelyan, T., Tananyan, A., Janoyan, N., Tadevosyan, A., Petrosyan, H., Hovhannisyan, A., Hayrapetyan, L., Arustamyan, M., Arnhold, J., Rotmann, A.-R., et al. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153218 · Cited by 203
Mendes, D., Alves, C., Afonso, N., Cardoso, F., Passos-Coelho, J. L., Costa, L., Andrade, S., & Batel-Marques, F. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0648-2 · Cited by 187
“[8]).”
Self-citationBreast cancer treatment: A phased approach to implementation
Mutebi, M., Anderson, B. O., Duggan, C., Adebamowo, C., Agarwal, G., Ali, Z., Bird, P., Bourque, J., DeBoer, R., Gebrim, L. H., et al. (2020) · Cancer · doi:10.1002/cncr.32910 · Cited by 187
“In contrast, locally advanced breast cancers (LABCs) are often best managed by initial systemic therapy to downstage disease followed by timely surgery, appropriate adjuvant radiotherapy, and protocol-driven postoperative systemic therapy administered to the completion of the prescribed course.(14) Although the majori…”
BackgroundMartín, M., Chan, A., Dirix, L., O’Shaughnessy, J., Hegg, R., Manikhas, A., Shtivelband, M., Krivorotko, P., Batista López, N., Campone, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw562 · Cited by 180
“Taxane-based chemotherapy is an effective first-line treatment option for women with human epidermal growth factor receptor 2-negative (HER2–) locally advanced/metastatic breast cancer [1, 2].”
BackgroundManagement of locally advanced breast cancer—perspectives and future directions
Tryfonidis, K., Senkus, E., Cardoso, M. J., & Cardoso, F. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.13 · Cited by 173
Self-citationChallenges in the management of advanced, ER-positive, HER2-negative breast cancer
Hart, C. D., Migliaccio, I., Malorni, L., Guarducci, C., Biganzoli, L., & Di Leo, A. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.99 · Cited by 169
Self-citationMiller, K., Cortes, J., Hurvitz, S. A., Krop, I. E., Tripathy, D., Verma, S., Riahi, K., Reynolds, J. G., Wickham, T. J., Molnar, I., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2385-z · Cited by 168
“are recommended in treatment guidelines [11, 14, 15].”
Self-citationOptimal management of hormone receptor positive metastatic breast cancer in 2016
Reinert, T., & Barrios, C. H. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015608993 · Cited by 168
Self-citationEndocrine treatment in breast cancer: Cure, resistance and beyond
Tryfonidis, K., Zardavas, D., Katzenellenbogen, B. S., & Piccart, M. J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.08.008 · Cited by 153
Self-citationPrat, A., Cheang, M. C. U., Galván, P., Nuciforo, P. G., Paré, L., Adamo, B., Muñoz-Mateu, M., Viladot, M., Press, M. F., Gagnon, R., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0922 · Cited by 134
Iwata, H., Im, S., Masuda, N., Im, Y., Inoue, K., Rai, Y., Nakamura, R., Kim, J. H., Hoffman, J., Zhang, K., et al. (2017) · Journal of Global Oncology · doi:10.1200/jgo.2016.008318 · Cited by 130
“Neutropenia* 67 (92) 54 (74) 13 (18) 2 (7) 0 0 212 (78) 135 (50) 21 (8) 4 (3) 0 1 (0.”
InfluentialSchettini, F., Buono, G., Cardalesi, C., Desideri, I., Placido, S. D., & Mastro, L. D. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.03.012 · Cited by 144
Vuylsteke, P., Huizing, M. T., Petráková, K., Roylance, R. R., Laing, R. W., Chan, S. Y. T., Abell, F., Gendreau, S. B., Rooney, I. A., Apt, D., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw320 · Cited by 120
Musolino, A., Campone, M., Neven, P., Denduluri, N., Barrios, C. H., Cortés, J., Blackwell, K., Soliman, H. H., Kahán, Z., Bonnefoi, H. R., et al. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0807-8 · Cited by 114
“Currently, endocrine therapy is recommended as initial therapy for patients with HR, HER2 advanced breast cancer [8, 9].”
BackgroundSelf-citationSchettini, F., Giuliano, M., Placido, S. D., & Arpino, G. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.09.004 · Cited by 110
Pivot, X. B., Marme, F., Koenigsberg, R., Guo, M., Berrak, E., & Wolfer, A. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw203 · Cited by 110
“Long-term survival of women with advanced or metastatic breast cancer (MBC) remains poor [1, 2] with no single accepted standard of care once initial chemotherapy has failed [2, 3].”
BackgroundZhang, Q. Y., Sun, T., Yin, Y. M., Li, H. P., Yan, M., Tong, Z. S., Oppermann, C. P., Liu, Y. P., Costa, R. L. D. P., Li, M., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920963925 · Cited by 112
Pe, M. L., Dorme, L., Coens, C., Basch, E., Calvert, M., Campbell, A., Cleeland, C. S., Cocks, K., Collette, L., Dirven, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30418-2 · Cited by 103
Self-citationHan, D., Wu, G., Chang, C. F., Zhu, F., Xiao, Y., Li, Q., Zhang, T., & Zhang, L. (2015) · Oncotarget · doi:10.18632/oncotarget.5723 · Cited by 97
“In spite of many advances such as HER2 or VEGF targeting medicines, median overall survival of patients with advanced breast cancer is still only 2–3 years [2].”
BackgroundGhislain, I., Zikos, E., Coens, C., Quinten, C., Balta, V., Tryfonidis, K., Piccart, M. J., Zardavas, D., Nagele, E., Bjelic‐Radisic, V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30099-7 · Cited by 103
Self-citationVaidyanathan, G., McDougald, D. L., Choi, J., Koumarianou, E., Weitzel, D. H., Osada, T., Lyerly, H. K., & Zalutsky, M. R. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.171306 · Cited by 97
“Moreover, they are not informative about differences in HER2 levels between primary lesion and metastases or among different metastatic sites (8–10), leading to recommendations that a biopsy be obtained to evaluate target status in metastases before selecting an appropriate therapy (11).”
Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer
Reinert, T., Saad, E. D., Barrios, C. H., & Bines, J. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00026 · Cited by 98
Self-citationJohnston, S. R. D. (2015) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv212 · Cited by 92
“Historically, international guidelines state that at the time of progression on endocrine treatment alternative endocrine therapies are still considered appropriate for patients with ER+ MBC, in particular for those patients with low disease burden and evidence of a prior good response to first-line endocrine treatmen…”
BackgroundConsensus on precision medicine for metastatic cancers: a report from the MAP conference
Swanton, C., Soria, J., Bardelli, A., Biankin, A. V., Caldas, C., Chandarlapaty, S., de Koning, L., Dive, C., Feunteun, J., Leung, S.-Y., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw192 · Cited by 95
“These include expression of the estrogen receptor (ER), progesterone receptor (PgR) and Her2 proteins, together with BRCA1 and BRCA2 mutations [11].”
BackgroundSelf-citationSchöffski, P., Cresta, S., Mayer, I. A., Wildiers, H. P. M. W., Damian, S., Gendreau, S. B., Rooney, I. A., Morrissey, K. M., Spoerke, J. M., Ng, V., et al. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1015-x · Cited by 93
“In patients with HER2-positive locally recurrent or metastatic breast cancer, therapies include the antibody–drug conjugate ado-trastuzumab emtansine and the combination of the monoclonal antibodies trastuzumab and pertuzumab, both of which target HER2, with either docetaxel or paclitaxel [1, 2].”
BackgroundSelf-citationPerez, E. A., Awada, A. H., O’Shaughnessy, J., Rugo, H. S., Twelves, C. J., Im, S., Gómez-Pardo, P., Schwartzberg, L. S., Dieras, V. C., Yardley, D. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00332-0 · Cited by 91
Self-citationThe Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer
Blackwell, K., Gligorov, J., Jacobs, I. A., & Twelves, C. J. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.01.006 · Cited by 91
Self-citation18F-FDG PET/CT in breast cancer: Evidence-based recommendations in initial staging
Caresia-Aróztegui, A. P., Vicente, A. M. G., Ruiz, S. Á., Bolton, R. C. D., Rincón, J. O., Garzón, J. R. G., Torres, M. D. A., & García‐Velloso, M. J. (2017) · Tumor Biology · doi:10.1177/1010428317728285 · Cited by 89
Berkowitz, M. J., Thompson, C. K., Zibecchi, L., Lee, M. K., Streja, E., Berkowitz, J. S., Wenziger, C. M., Baker, J. L., DiNome, M. L., & Attai, D. J. (2020) · Journal of Cancer Survivorship · doi:10.1007/s11764-020-00908-5 · Cited by 101
“pact quality of life may go under-reported and therefore undertreated in this patient population [67].”
BackgroundSammons, S. L., Topping, D. L., & Blackwell, K. (2017) · Current Cancer Drug Targets · doi:10.2174/1568009617666170330120452 · Cited by 95
Self-citationResearch needs in breast cancer
Cardoso, F., Harbeck, N., Barrios, C. H., Bergh, J. C. S., Cortés, J., Saghir, M. Z., Francis, P. A., Hudis, C. A., Ohno, S., Partridge, A. H., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw571 · Cited by 96
“Although the survival of metastatic breast cancer patients has been improving over the years, the median overall survival remains at 2–3 years, although this is widely variable among subtypes [69, 70].”
BackgroundSelf-citationSefrioui, D., Perdrix, A., Sarafan‐Vasseur, N., Dolfus, C., Dujon, A., Picquenot, J., Delacour, J., Cornic, M., Bohers, É., Leheurteur, M., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29612 · Cited by 94
“Aromatase inhibitors (AI) or tamoxifen is the recommended first line hormonal therapy in postmenopausal HR1 metastatic breast cancer (MBC).(1,2) Nevertheless, disease progression is usually observed within a few months after treatment initiation.”
Spring, L. M., Bardia, A., & Modi, S. (2016) · PubMed · Cited by 102
Breast Cancer Under Age 40: a Different Approach
Ribnikar, D., Ribeiro, J. M., Pinto, D., Sousa, B., Pinto, A. C., Gomes, E., Moser, E. C., Cardoso, M. J., & Cardoso, F. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0334-8 · Cited by 89
Self-citationCardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients
Foglietta, J., Inno, A., Iuliis, F. D., Sini, V., Duranti, S., Turazza, M., Tarantini, L., & Gori, S. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.07.003 · Cited by 92
“The preferred first-line endocrine therapy for post menopausal patients is an AI or tamoxifen, depending on type and duration of the adjuvant endo crine therapy [27-30].”
BackgroundPrognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013
King, T. A., Lyman, J. P., Gönen, M., Voci, A. E., Brot, M. D., Boafo, C., Sing, A. P., Hwang, E. S., Alvarado, M. D., Liu, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.1960 · Cited by 86
“15 Bone 14 (64) 16 (55) 18 (36) Visceral 2 (9) 4 (14) 18 (36) Both 1 (5) 2 (7) 3 (6) Other† 5 (23) 7 (24) 11 (22) No.”
Self-citationMistry, R. A., May, J. R., Suri, G., Young, K. C., Brixner, D. I., Oderda, G. M., BISKUPIAK, J. E., Tang, D. H., Bhattacharyya, S., Mishra, D., et al. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.6.514 · Cited by 85
“However, clinical resistance to hormonal therapy due to increased expression of growth factor receptor pathways eventually occurs in most patients, leading to disease progression.(4) Cyclin-dependent kinase (CDK) 4 and 6 inhibitors (e.”
BackgroundGoetz, M. P., Suman, V. J., Reid, J. M., Northfelt, D., Mahr, M. A., Ralya, A. T., Kuffel, M. J., Buhrow, S. A., Safgren, S. L., McGovern, R. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.3246 · Cited by 90
Targeted therapies for ER+/HER2- metastatic breast cancer
Yamamoto‐Ibusuki, M., Arnedos, M., & André, F. (2015) · BMC Medicine · doi:10.1186/s12916-015-0369-5 · Cited by 95
Self-citationLobbezoo, D. J. A., van Kampen, R. J. W., Voogd, A. C., Dercksen, M. W., van den Berkmortel, F. W. P. J., Smilde, T. J., van de Wouw, A. J., Peters, F. P. J., van Riel, J., Peters, N. A. J. B., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv544 · Cited by 82
Rodriguez, D. A., Ramkairsingh, M., Lin, X., Kapoor, A., Major, P. P., & Tang, D. (2019) · Cancers · doi:10.3390/cancers11071028 · Cited by 85
“For advanced BCs, ETR can be rapidly developed; these tumors are defined as relapse arisen within two years of endocrine therapy or one year after completion of adjuvant hormone therapy according to the recent ESO-ESMO (European School of Oncology-European Society for Medical Oncology) guidelines [29,30].”
MethodIm, S., Mukai, H., Park, I. H., Masuda, N., Shimizu, C., Kim, S.-B., Im, Y., Ohtani, S., Bartlett, C. H., Lu, D. R., et al. (2019) · Journal of Global Oncology · doi:10.1200/jgo.18.00173 · Cited by 82
“However, de novo and acquired resistance to endocrine therapy can develop, which often results in a therapeutic switch to chemotherapy that is associated with clinically significant toxicity.(5) Treatment options that improve outcomes with endocrine-based therapy and delay the use of chemotherapy are needed.”
BackgroundClinically Meaningful Use of Blood Tumor Markers in Oncology
Holdenrieder, S., Pagliaro, L. C., Morgenstern, D. E., & Dayyani, F. (2016) · BioMed Research International · doi:10.1155/2016/9795269 · Cited by 87
“However, recent research has shown superior performance using a combination of multiple TMs as a panel for assessment, or as part of validated algorithms that also incorporate other clinical factors.”
MethodCristofanilli, M., DeMichele, A. M., Giorgetti, C., Turner, N. C., Slamon, D. J., Im, S., Masuda, N., Verma, S., Loi, S., Colleoni, M. A., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.08.011 · Cited by 76
“Considerable effort has been made to improve the efficacy of endocrine-based therapies to delay the use of chemotherapy and optimise both the length and quality of life of patients [1].”
BackgroundContostavlos, D. L. (1971) · PubMed · Cited by 75
Bardia, A., Parton, M., Kümmel, S., Estévez, L. G., Huang, C.-S., Cortés, J., Ruiz-Borrego, M., Telli, M. L., Martin-Martorell, P., López, R., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.8392 · Cited by 72
“TNBC is associated with a worse prognosis and higher mortality than other breast cancers, and intense efforts are ongoing to develop therapies targeted to TNBC molecular subtypes.(1,15) In this trial, a GS-based biomarker for LCL161 sensitivity was used to prospectively stratify patients to receive neoadjuvant LCL161…”
MethodMetastatic ER+ Breast Cancer: Mechanisms of Resistance and Future Therapeutic Approaches
Raheem, F., Karikalan, S. A., Batalini, F., Masry, A. E., & Mina, L. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216198 · Cited by 84
“…months of completing adjuvant ET or progression 6 Secondary or acquired resistance is defined as disease recurrence after the first two years of adjuvant ET, within 12 months of completing adjuvant ET or progression 6 months after initiating ET for MBC [5]. months after initiating ET for MBC [5].”
MethodJérusalem, G., Mariani, G., Ciruelos, E., Martín, M., Tjan‐Heijnen, V. C. G., Neven, P., Gavila, J. G., Michelotti, A., Montemurro, F., Generali, D., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw249 · Cited by 76
“Given that globally relevant clinical practice guidelines for breast cancer recommend EVE plus AIs including EXE as a treatment option for patients with HR+, HER2−ABC recurring or progressing on/after prior NSAIs [1, 17], these data add safety information to the clinical relevance of the efficacy data.”
BackgroundMukai, H., Shimizu, C., Masuda, N., Ohtani, S., Ohno, S., Takahashi, M., Yamamoto, Y., Nishimura, R., Sato, N., Ohsumi, S., et al. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-018-1353-9 · Cited by 75
Delaloge, S., Pérol, D., Courtinard, C., Brain, E. G. C., Asselain, B. J. R., Bachelot, T., Debled, M., Dieras, V. C., Campone, M., Lévy, C., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw260 · Cited by 72
“Systemic treatment includes chemo-, endocrine, and targeted therapies, according to factors such as hormone receptors, endocrine resistance, visceral crisis, previous adjuvant therapy, and relapse-free interval [1].”
BackgroundValidated biomarkers: The key to precision treatment in patients with breast cancer
Duffy, M. J., O’Donovan, N., McDermott, E. W. M., & Crown, J. P. (2016) · The Breast · doi:10.1016/j.breast.2016.07.009 · Cited by 85
“Despite its high cost [55], American [56] and European [57] guidelines recommend combined treatment with trastuzumab, pertuzumab and chemotherapy in patients with advanced HER2-positive breast cancer.”
BackgroundCoïsson, M., Barrera, G., Celegato, F., Martino, L., Kane, S. N., Raghuvanshi, S., Vinai, F., & Tiberto, P. M. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.12.006 · Cited by 73
Hortobágyi, G. N. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1050-7 · Cited by 69
Zhang, Q., Li, L., & Jing, D. (2020) · Oncology Reports · doi:10.3892/or.2020.7770 · Cited by 85
Liver Metastases From Breast Cancer: What Role for Surgery? Indications and Results
Golse, N., & Adam, R. A. (2017) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.12.012 · Cited by 65
“also reported their experience of r peat Hx, with a mean survival rate after the second Hx of 46 months [33-115], which was longer t han that achieved after exclusively systemic therapy (45).”
BackgroundRole of Bisphosphonates in Breast Cancer Therapy
Goldvaser, H., & Amir, E. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0623-8 · Cited by 64
Receptor conversion in metastatic breast cancer: analysis of 390 cases from a single institution
Chen, R., Qarmali, M., Siegal, G. P., & Wei, S. (2020) · Modern Pathology · doi:10.1038/s41379-020-0615-z · Cited by 64
Zhang, P., Sun, T., Zhang, Q., Yuan, Z., Jiang, Z., Wang, X. J., Cui, S., Teng, Y., Hu, X., Yang, J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30088-8 · Cited by 68
Self-citationPonde, N. F., Bradbury, I., Lambertini, M., Ewer, M. S., Campbell, C., Ameels, H., Zardavas, D., Cosimo, S. D., Baselga, J. M., Huober, J., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4628-3 · Cited by 65
“Nevertheless, it remains an important therapeutic alternative in patients with advanced disease [6, 10].”
BackgroundSelf-citationBreast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches
Schick, J., Ritchie, R. P., & Restini, C. B. A. (2021) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223421995854 · Cited by 74
Cardoso, F., Harbeck, N., Mertz, S. A., & Fenech, D. (2016) · The Breast · doi:10.1016/j.breast.2016.04.004 · Cited by 61
“The international consensus guidelines for ABC management developed at ABC1 and ABC2 specifically address these issues and have been adopted by several countries [4,20].”
BackgroundSelf-citationHua, X., Long, Z., Huang, X., Deng, J., Wen, W., He, Z., Guo, L., Zhang, W., & Lin, H. (2020) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2020.100560 · Cited by 60
Adjuvant trastuzumab: a 10-year overview of its benefit
Lambertini, M., Ponde, N. F., Solinas, C., & de Azambuja, E. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1264876 · Cited by 63
Bonotto, M., Gerratana, L., Maïo, M. D., Angelis, C. D., Cinausero, M., Moroso, S., Milano, M., Stanzione, B., Gargiulo, P., Iacono, D., et al. (2016) · The Breast · doi:10.1016/j.breast.2016.10.021 · Cited by 59
The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer
Pejerrey, S. M., Dustin, D. J., Kim, J.-A., Gu, G., Rechoum, Y., & Fuqua, S. A. W. (2018) · Hormones and Cancer · doi:10.1007/s12672-017-0306-5 · Cited by 64
“endocrine therapy for metastatic breast cancer (MBC) [5, 6].”
Bonechi, M., Galardi, F., Biagioni, C., Luca, F. D., Bergqvist, M., Neumüller, M., Guarducci, C., Boccalini, G., Gabellini, S., Migliaccio, I., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24700 · Cited by 55
Sousa, B., Ribeiro, J. M., Ribnikar, D., & Cardoso, F. (2016) · Springer eBooks · doi:10.1007/978-3-319-46356-8_24 · Cited by 57
Self-citationTian, T., Zhao, Y., Zheng, J., Jin, S., Liu, Z., & Wang, T. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.06.017 · Cited by 54
Clinical utility of 18F-FDG-PET/MR for preoperative breast cancer staging
Botsikas, D., Kalovidouri, A., Becker, M., Copercini, M., Djema, D. A., Bodmer, A., Monnier, S., Becker, C. D., Montet, X., Delattre, B. M. A., et al. (2015) · European Radiology · doi:10.1007/s00330-015-4054-z · Cited by 54
Kümler, I., Knoop, A. S., Jessing, C., Ejlertsen, B., & Nielsen, D. L. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000062 · Cited by 54
“Recent treatment guidelines from a range of countries recommend addition of everolimus to exemestane for patients recurring/progressing during or following an NSAI even in the presence of visceral disease.(57) 58 83 84 Currently, three specific CDK4/6 inhibitors palbociclib, abemaciclib and ribociclib are being tested…”
BackgroundInfluentialForce, J. M., Leal, J. H. S., & McArthur, H. L. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0634-5 · Cited by 52
Metadata
- Authors
- Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., Cardoso, M. J., Cufer, T., El Saghir, N., Fallowfield, L., Fenech, D., Francis, P., Gelmon, K., Giordano, S. H., Gligorov, J., Goldhirsch, A., Harbeck, N., Houssami, N., Hudis, C., Kaufman, B., Krop, I., Kyriakides, S., Lin, U. N., Mayer, M., Merjaver, S. D., Nordström, E. B., Pagani, O., Partridge, A., Penault-Llorca, F., Piccart, M. J., Rugo, H., Sledge, G., Thomssen, C., van't Veer, L., Vorobiof, D., Vrieling, C., West, N., Xu, B., & Winer, E.
- Affiliations
- Centro Champalimaud (PT)
- European School of Oncology (CH)
- Memorial Sloan Kettering Cancer Center (US)
- Gdańsk Medical University (PL)
- Clinique de Genolier (CH)
- Institut Gustave Roussy (FR)
- Pontifícia Universidade Católica do Rio Grande do Sul (BR)
- Karolinska University Hospital (SE)
- Fondazione Sandro Pitigliani (IT)
- Duke University (US)
- Champalimaud Foundation (PT)
- Brighton and Sussex Medical School (GB)
- Europa Donna (IT)
- Peter MacCallum Cancer Centre (AU)
- BC Cancer Agency (CA)
- The University of Texas MD Anderson Cancer Center (US)
- Université Pierre-et-Marie-Curie (FR)
- European Institute of Oncology (IT)
- Ludwig-Maximilians-Universität München (DE)
- The University of Sydney (AU)
- Sheba Medical Center (IL)
- Dana-Farber Cancer Institute (US)
- University of Michigan (US)
- Europa Donna (GE)
- Istituto Oncologico della Svizzera Italiana (CH)
- Centre Jean Perrin (FR)
- Institut Jules Bordet (BE)
- University of California, San Francisco (US)
- Indiana University (US)
- Martin Luther University Halle-Wittenberg (DE)
- Cardiff and Vale University Health Board (GB)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Corresponding author
- Cardoso, F.
- ORCID
- Cardoso, F.
- Costa, A.
- Norton, L.
- Senkus, E.
- Aapro, M.
- André, F.
- Barrios, C.H.
- Bergh, J.
- Biganzoli, L.
- Cardoso, M.J.
- Fallowfield, L.
- Francis, P.
- Gelmon, K.
- Giordano, S.H.
- Gligorov, J.
- Harbeck, N.
- Houssami, N.
- Hudis, C.
- Kaufman, B.
- Krop, I.
- Pagani, O.
- Partridge, A.
- Penault-Llorca, F.
- Piccart, M.J.
- Rugo, H.
- Sledge, G.
- Thomssen, C.
- Vorobiof, D.
- Vrieling, C.
- Xu, B.
- Winer, E.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2014-10
- Volume
- 25
- Issue
- 10
- Pages
- 1871-1888
- ISSN
- 0923-7534 (ISSN-L)
- PMC
- PMC4176456
- OpenAlex
- W2127287298
- Cited by
- 540
- References
- 143
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 15 · 2023: 23 · 2022: 20 · 2021: 24 · 2020: 38 · 2019: 37 · 2018: 57 · 2017: 107 · 2016: 124 · 2015: 84 · 2014: 2
- FWCI
- 33.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 1878 d)
- Locations
- Annals of Oncology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
- Sussex Research Online (University of Sussex) (submittedVersion, cc-by-nc-nd)
- OAR@UM (University of Malta) (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Figshare (submittedVersion, cc-by-nc-nd)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- advanced breast cancer, metastatic breast cancer, treatment guidelines, HER2-positive breast cancer, luminal breast cancer, overall survival, quality of life, standard of care, unmet medical needs, research priorities
- MeSH terms
- Breast Neoplasms, Female, Humans, Treatment Outcome, Guidelines as Topic, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.